GILD News 90.54 07/25/2014 05:10:48 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 90.54 $GILD

Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences   turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...

Final Glance: Biotechnology companies
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...

3 Crucial Quotes From Gilead Sciences Stock
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:05PM CDT
Gilead Sciences is a long-standing leader in HIV treatment, but its sales of its hepatitis C drug Sovaldi that's driving the company's revenue surge. While Sovaldi's sales are soaring, investors are right to wonder if the drug's break neck...

Avella Chosen as Specialty Pharmacy Partner for Zydelig(R)
Newsfile Corp - Thu Jul 24, 3:29PM CDT
full story)

What Gilead Stock's Latest Blockbuster Approval Means for Investors
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 3:01PM CDT
Source: Gilead Sciences Gilead Sciences   has won approval for its promising drug Zydelig in three important cancer indications. As a combination treatment alongside  Roche's    top selling Rituxan, the FDA green-light puts Zydelig head-to-head...

Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...

Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.

Most active Nasdaq-traded stocks
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:

Midday Glance: Biotechnology companies
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

3 Stocks Improving Performance Of The Health Care Sector
at The Street - Thu Jul 24, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...

Early Glance: Biotechnology companies
AP - Thu Jul 24, 10:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside
at The Street - Thu Jul 24, 10:11AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that shares of Gilead Sciences are not expensive given its growth rate.

Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."

Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.

Today's Momo Momentum Stock To Watch: Gilead (GILD)
at The Street - Thu Jul 24, 8:45AM CDT
Trade-Ideas LLC identified Gilead (GILD) as a momo momentum candidate

Gilead Sciences partners with the Medicines Patent Pool to expand access of TAF for HIV treatment in the developing world
M2 - Thu Jul 24, 6:52AM CDT
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) on Thursday launched a new agreement to expand access to its investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine's US regulatory approval in partnership with the Medicines Patent Pool (MPP).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 116

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 109

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 183

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 67

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 30

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
Veterans Find a Haven in Home Helpers® Franchise

Updated Category News Views 89

Veterans Thriving at Home Helpers® Tossing out a warm welcome to fresh horizons post-military, Home Helpers® Home Care is serving up more than just compassionate care—it’s become a bonafide haven for veterans diving into the world of franchising. This isn’t just an indie pat on the back; according to the latest scoop from Franchise Business Review, Home Helpers®...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Growth of the Digital Signage Market Today

Updated Category News Views 84

The digital signage market was transforming fast, with projections showing a jump from USD 20.1 billion in 2024 to around USD 27.3 billion by 2029—talk about a solid compound annual growth rate of 6.3%. Traders were buzzing over the factors driving this upward trend: high-res displays and expanding infrastructure in emerging markets had everyone seeing green. Market...

Continue Reading
Exploring the Potential of Healthcare Stocks Amid Market Growth

Updated Category News Views 189

The stock market is navigating through exciting times, with the S&P 500 recently eclipsing the significant milestone of 5,700 points. This robust performance is fueled by a dynamic shift as investors increasingly look towards emerging sectors, particularly healthcare, which is gaining momentum this earnings season. This year, we've seen an impressive trend, with over 40...

Continue Reading
Recognizing Excellence: Nominate for the Paralegal of the Year Award

Updated Category News Views 217

Nominations Now Open for the 2025 AAJ Paralegal of the Year Award The American Association for Justice (AAJ) proudly announces that nominations for the 2025 Paralegal of the Year Award are now open. This award, sponsored by Advocate Capital, Inc., is a wonderful opportunity to acknowledge and applaud the significant contributions of paralegals within our civil justice...

Continue Reading
Mavsign and RouteOne Revolutionize Automotive Deal Processes

Updated Category News Views 174

Mavsign and RouteOne Transforming Automotive Transactions Mavsign, renowned for its expertise in remote document signings and compliance solutions, has announced an exciting partnership with RouteOne, a leader in automotive financing solutions. This collaboration aims to enhance the efficiency and security of automotive transactions by integrating both companies'...

Continue Reading
Revance Stockholders Encouraged to Support Crown's Tender Offer

Updated Category News Views 122

Crown's Tender Offer for Revance Stock: Key Information Revance Therapeutics, Inc. (NASDAQ: RVNC) stockholders are being urged to support Crown Laboratories, Inc. by tendering their shares before the upcoming deadline. This is an important moment as Crown's tender offer presents the only current proposal post Teoxane's withdrawal. Details of the Crown Offer Crown has made...

Continue Reading